logo

For the Inventor, By the Inventor

London, United Kingdom

Cyclacel Limited


USPTO Granted Patents = 56

% Expired Patents = 51.8



Trademarks = 3

Forward Citations = 525

Loading Chart...
Loading Chart...

83 inventors (with patents filed for the assignee):

goldMedal Peter Martin Fischer (18 out of 20 patents)

silverMedal Shudong Wang (11 out of 13 patents)

bronzeMedal John Colyer (9 out of 12 patents)

4.  Simon Richard Green (8 out of 15 patents)

5.  Roger Kingdon Craig (7 out of 26 patents)

6.  Gavin Wood (6 out of 7 patents)

7.  Judy H Chiao (5 out of 11 patents)

8.  Robert Westwood (4 out of 17 patents)

9.  Stuart Donald Jones (4 out of 4 patents)

10.  Ian Fleming (4 out of 4 patents)

11.  Stuart Wilson (4 out of 4 patents)

12.  Paul Workman (4 out of 8 patents)

13.  Daniella I Zheleva (4 out of 4 patents)

14.  Christopher Meades (4 out of 5 patents)

15.  Edward McDonald (4 out of 22 patents)


Core Competencies:
Purine Derivatives
Pyrimidine Compounds
CDK Inhibitors
Acute Myeloid Leukemia
Sapacitabine
Combination Therapy
Protein Kinase Inhibitors
Anticancer Agents
Dosing Regimens
Crystalline Forms
Transport Vectors
Anti-Proliferative Compounds

56 patents:

1. 10927113 - Process for preparing purine derivatives (2021-02-23),
2. 10226478 - Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia (2019-03-12),
3. 9872874 - Dosage regimen for sapacitabine and seliciclib (2018-01-23),
4. 9675631 - Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine (2017-06-13),
5. 9573951 - Crystalline forms of a purine derivative (2017-02-21),
6. 9493471 - Pyrimidine derivatives as protein kinase inhibitors (2016-11-15),
7. 9173938 - Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders (2015-11-03),
8. 9133199 - Pyrimidine derivatives as protein kinase inhibitors (2015-09-15),
9. 8975239 - Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine (2015-03-10),
10. 8889861 - Crystalline forms of a purine derivative (2014-11-18),
11. 8884001 - Preparation of intermediates useful in the synthesis of 2'-cyano-2′-deoxy-N4-palmi-toyl-1-β-D-arabinofuranosylcytosine (2014-11-11),
12. 8846696 - Purine derivatives (2014-09-30),
13. 8809350 - Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases (2014-08-19),
14. 8592581 - Trisubstituted purine derivatives (2013-11-26),
15. 8563542 - Pyrimidine derivatives as protein kinase inhibitors (2013-10-22),
Cyclacel Limited is a biotechnology company based in London, specializing in the development of innovative cancer treatment compounds. The company focuses on advancing therapies that target critical pathways in cancer cells, particularly through the use of purine and pyrimidine derivatives, as well as CDK inhibitors. Cyclacel's research is centered on addressing acute myeloid leukemia and enhancing treatment efficacy through combination therapies, positioning it as a key player in the oncology sector.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Cyclacel Limited
56 Patents

#75 in London

#316 in United Kingdom

#12,732 in the World

London, GB
London, United Kingdom

Cyclacel Limited

Forward Citations = 525

83 inventors:

goldMedal Peter Martin Fischer (18 out of 20 patents)

silverMedal Shudong Wang (11 out of 13 patents)

bronzeMedal John Colyer (9 out of 12 patents)

4.  Simon Richard Green (8 out of 15 patents)

5.  Roger Kingdon Craig (7 out of 26 patents)

Please report any incorrect information to [email protected]
Loading…